Investment Rating - The industry investment rating is "Outperform" [1] Core Viewpoints - The report emphasizes the potential of second-generation 4-1BB agonists, particularly dual-target antibodies, which have shown promising efficacy while addressing safety concerns associated with liver toxicity [4][24] - The report highlights significant recent industry events, including Merck's acquisition of Cidara for approximately $9.2 billion and Pfizer's acquisition of Metsera, indicating a trend of consolidation in the biopharmaceutical sector [6] - The report suggests a long-term positive outlook for China's innovative drug sector, driven by increasing data catalysts and new product sales, recommending specific companies for investment [6] Summary by Sections 4-1BB Overview - 4-1BB (CD137) is a key member of the tumor necrosis factor receptor superfamily, crucial for T cell activation and immune response enhancement [4][10] - The second-generation CAR-T cell technology utilizing 4-1BB has been validated for inducing prolonged activation and survival of CAR-T cells in vivo [4][12] First-Generation 4-1BB Agonists - First-generation 4-1BB agonists like urelumab and utomilumab faced limitations due to liver toxicity and insufficient efficacy [16][22] - Urelumab demonstrated significant hepatotoxicity at doses ≥1.0 mg/kg, leading to its discontinuation [21][22] Second-Generation 4-1BB Agonists - Second-generation 4-1BB agonists are primarily dual-specific antibodies targeting various pathways, with a focus on balancing efficacy and safety [24][26] - LBL-024, a promising candidate, has shown unprecedented efficacy and is expected to submit a BLA by Q3 2026 [4][6] Recent Industry Events - Merck's acquisition of Cidara for $9.2 billion and Pfizer's acquisition of Metsera highlight ongoing consolidation in the biopharmaceutical industry [6] - The report notes that the innovative drug sector is under pressure but is expected to rebound with a focus on companies with strong revenue capabilities [6] Investment Strategy - The report recommends focusing on companies with differentiated innovation pipelines and strong revenue capabilities, including specific biopharma and pharma leaders [6] - Suggested companies for investment include Innovent Biologics, BeiGene, and I-MAB, among others [6]

Core Viewpoint - Moer Technology has officially announced its IPO on the Sci-Tech Innovation Board, setting the issue price at 114.28 yuan per share, making it the highest-priced new stock of the year and the only stock priced over 100 yuan in 2023 [3][4]. Group 1: IPO Details - The company plans to issue 70 million shares, aiming to raise approximately 7.9996 billion yuan, with a net amount of about 7.576 billion yuan, positioning it as the second-largest IPO in A-shares this year, following Huadian New Energy [3][5]. - The funds raised will primarily be used for the development of next-generation AI training and inference chips, graphics chips, and AI SoC chips, as well as to supplement working capital [3][5]. - The IPO expenses (excluding VAT) amount to 424 million yuan, with CITIC Securities as the sponsor and Ernst & Young Hua Ming as the accounting firm [3][5]. Group 2: Company Overview - Moer Technology is a leading domestic GPU manufacturer, and its listing will mark it as the "first domestic GPU stock" [4]. - The company focuses on the research, design, and sales of GPUs and related products, having launched four generations of GPU architectures since its establishment in 2020 [5]. - Moer Technology has not yet achieved profitability, with revenues of 46 million yuan, 124 million yuan, and 438 million yuan from 2022 to 2024, and net losses of 1.894 billion yuan, 1.703 billion yuan, and 1.618 billion yuan during the same period [5]. - The revenue growth rate from 2022 to 2024 is 208.44%, with significant R&D investments, accounting for 2422.51%, 1076.31%, 309.88%, and 79.33% of total revenue during the respective periods [5].

Group 1 - The report highlights a strategic shift towards large financial and consumer sectors, indicating a rebound window following the maximum negative impact from equal tariffs [1][9] - The report emphasizes that the market is approaching a phase bottom, with short-term adjustments not altering the long-term upward trend, despite liquidity pressures from the Federal Reserve's hawkish stance [2][9] - Historical analysis of the U.S. stock market shows that significant downturns typically require major negative shocks, with expected maximum adjustments around 10% in the current context [3][10][11] Group 2 - The report notes that market volume has decreased, with transaction amounts falling below 20 trillion yuan, indicating a lack of momentum in market leadership [4][12] - It suggests that the current market adjustment presents a good opportunity for accumulation, focusing on sectors with favorable risk-reward ratios, such as real estate and resource commodities [4][13][14] - The report identifies mid-term investment opportunities in high-growth sectors, waiting for renewed confidence in high-prosperity segments like storage and AI [4][13][14]

Core Viewpoint - The Hong Kong stock market has entered a correction phase since October, primarily due to previous significant gains, tightening dollar liquidity, and a decline in expectations for Federal Reserve rate cuts. However, the ongoing AI wave and the influx of incremental capital suggest that the bull market in Hong Kong stocks is likely to continue [1][2][13]. Market Adjustment - Since the beginning of the year, the Hong Kong stock market has performed well, with the Hang Seng Index and Hang Seng Tech reaching new highs in early October. However, by mid-October, the market began to adjust, with the Hang Seng Index experiencing a maximum decline of 5.1% and Hang Seng Tech a maximum decline of 8.1% [2]. - The Hang Seng Index and Hang Seng Tech recorded maximum gains of 47% and 61% respectively this year before entering the current adjustment phase [2]. Factors Influencing the Market - The tightening of dollar liquidity and the decline in expectations for Federal Reserve rate cuts have pressured the Hong Kong stock market. The U.S. government shutdown led to a temporary halt in government spending, causing dollar liquidity to tighten [3]. - Despite the end of the government shutdown, economic data remains unclear, leading to cautious Federal Reserve rate cut decisions. The market's expectation for a 25 basis point cut in December has dropped to 40% [3]. - The significant prior gains in the Hong Kong stock market, coupled with rising concerns over AI bubbles, have created selling pressure. The Hang Seng Tech Index has seen a maximum increase of 61% this year, while the Hang Seng Biotech Index has increased by 130% [3][8]. Historical Context of Market Corrections - In bull markets, adjustments are common, categorized into small corrections (average maximum decline of about 7%) and large corrections (average maximum decline of about 17%). Small corrections typically occur due to short-term market sentiment disturbances, while large corrections are often linked to liquidity tightening or external shocks [7][8]. - Historical data shows that small corrections in the Hang Seng Index average a maximum decline of 6.5% and last about 12 trading days, while large corrections average a maximum decline of 17% and last about 53 trading days [7][8]. Future Outlook - The tightening dollar liquidity is viewed as a short-term disturbance, and the AI wave is expected to continue. The release of previously accumulated liquidity following the end of the U.S. government shutdown may support the Hong Kong stock market [13]. - Incremental capital inflows and the gathering of quality assets suggest that the bull market in Hong Kong stocks may continue. The unique characteristics of Hong Kong assets, particularly in the context of the ongoing transformation in the domestic economy, enhance their attractiveness [13][14]. - Southbound capital is expected to continue flowing into the Hong Kong market, with over 1.3 trillion yuan already invested this year. This trend is likely to be supported by institutional investors, further propelling the market upward [14].

Investment Rating - The report maintains a positive outlook on the oral cyclic peptide drugs, highlighting their potential to reshape the treatment landscape in various therapeutic areas [15][20]. Core Insights - The report emphasizes the significant potential of multiple oral cyclic peptide drugs, particularly in the treatment of chronic diseases, where patient convenience and safety are paramount [19][20]. - It identifies the oral PCSK9 inhibitors as a promising class of drugs that could transform lipid-lowering therapy, addressing the limitations of traditional statins [20][27]. - The report also discusses the advancements in oral IL-23 antagonists for psoriasis treatment, indicating a strong potential for expanding indications [44][49]. Summary by Sections Market Overview - The report notes a decline in the medical sector, with the CITIC medical index dropping by 6.76%, underperforming the CSI 300 index by 2.99 percentage points, ranking 25th among 30 sectors [8]. Innovative Drugs - The report highlights a shift in the domestic innovative drug industry from quantity to quality, suggesting a focus on differentiated products and international pipelines by 2025 [12]. - It recommends monitoring companies such as BeiGene, Innovent, and others for their promising product pipelines [12]. Medical Devices - The report indicates a recovery in bidding volumes for imaging equipment and a growing home medical device market, with companies like Mindray and United Imaging being key players [12]. - It also notes the potential for domestic companies to gain market share through the replacement of imported products in the light-emitting device sector [12]. Oral Cyclic Peptides - The report discusses the advancements in oral cyclic peptide drugs, which have shown improved bioavailability and patient compliance compared to traditional peptide therapies [19][20]. - It highlights the clinical success of MK-0616, an oral PCSK9 inhibitor, which has demonstrated significant LDL-C reduction in clinical trials [43][44]. Psoriasis Treatment - The report outlines the potential of JNJ-2113, an oral IL-23 receptor antagonist, which has shown promising results in clinical trials for psoriasis, with a high percentage of patients achieving treatment goals [55][57]. - It emphasizes the growing market for oral therapies in chronic conditions, driven by patient demand for more convenient treatment options [44][49]. Industry Beneficiaries - The report identifies several CXO companies that are well-positioned to benefit from the growing cyclic peptide market, including WuXi AppTec and others, due to their advanced synthesis capabilities [63][65]. - It suggests that the global cyclic peptide market is expected to expand rapidly as more significant products are launched [65].

Core Viewpoints - The current adjustment is characterized as a "doubtful bull market level," indicating that the major trends in the AI industry chain have not ended, although there are short-term fluctuations and a temporary lack of cost-effectiveness in large trends. This situation resembles historical patterns observed in early 2014, early 2018, and early 2021 [1][3][5] - The "two-stage bull market theory" remains unchanged, suggesting that the transition from Bull Market 1.0 to 2.0 is a typical feature of the A-share bull market cycle. The transition period is expected to occur in the first half of 2026, with a full bull market potentially starting in the second half of 2026 [1][5][6] Summary by Sections Adjustment Phase - The adjustment phase is seen as a "doubtful bull market level," where the AI industry chain is experiencing a lack of cost-effectiveness, leading to a market correction. Historical experiences indicate that such adjustments are typical and often occur in quarterly cycles [3][4] - The current market conditions show that the implied equity risk premium (ERP) in sectors like telecommunications and electronics is still above historical lows, while the price-to-earnings (PE) ratios are at absolute historical highs [3][4] Spring Market Outlook - The spring market is expected to be more promising post-adjustment, with economic growth needing to maintain a high level to achieve the 2035 medium-developed country goal. The third quarter of 2025 showed weak economic performance, and December 2025 is seen as a critical window for laying out economic policies for 2026 [6][7] - The technology sector is anticipated to see a rapid improvement in cost-effectiveness, with institutional investors reducing their technology holdings in the short term. The micro-structural improvements in the technology sector are also expected to play a significant role in the spring market rotation [6][7] 2026 Industry Style and Rhythm Outlook - The transition from Bull Market 1.0 to 2.0 is expected to favor high-dividend defensive stocks. The actual improvement in economic sentiment will catalyze cyclical stocks to lead index breakthroughs, with technology trends and manufacturing global influence being the main themes of the bull market [8] - In the spring of 2026, the early validation of policy bottoms, cyclical price increases, and improved year-on-year PPI expectations will provide a foundation for cyclical assets. Key areas of focus include basic chemicals, industrial technology, innovative pharmaceuticals, and defense industries, with potential rebounds in AI computing power, storage, energy storage, and robotics [8]

Group 1 - The report indicates that the current adjustment phase is characterized as a "doubtful bull market level," with the AI industry chain experiencing a significant trend that has not yet ended, while smaller fluctuations are present and the cost-effectiveness of large trends is temporarily insufficient. This situation resembles historical patterns observed in early 2014 with the ChiNext, early 2018 with food and beverage, and early 2021 with new energy [4][6][7] - The "bull market two-stage theory" remains unchanged, confirming the high-level area of the bull market 1.0 phase. The transition from bull market 1.0 to 2.0 is expected to occur in the first half of 2026, with a focus on the accumulation of conditions for a comprehensive bull market and adjustments in industry trends to digest cost-effectiveness issues [6][7][9] - The report emphasizes that while adjustments are occurring, it is crucial to maintain a firm belief in the bull market. The adjustment phase is seen as a potential bottom, particularly when it aligns with the core track's bull-bear boundary [6][7] Group 2 - The report expresses optimism for the spring market following the adjustment, highlighting that achieving the 2035 medium-developed country goal requires maintaining a high economic growth rate. The economic performance in Q3 2025 was weak, and December 2025 is identified as a critical window for laying out economic policies for 2026, with the possibility of an early verification of the "policy bottom" [7][8] - Two key clues for the spring market are discussed: first, the management's emphasis on economic growth and the potential early verification of the "policy bottom"; second, the mid-term upward trend of the technology industry remains unchanged, with the AI industry still in "stage 3" and moving towards "stage 4," indicating non-linear growth in industry profits [8][9] - The report anticipates that the transition from bull market 1.0 to 2.0 will favor high-dividend defensive strategies, with the actual improvement in economic sentiment catalyzing a breakthrough in cyclical stocks, while the technology industry's trend and global influence of manufacturing will be the main lines of the bull market [9] Group 3 - The report outlines expectations for the 2026 industry style rhythm, indicating that cyclical stocks may serve as the foundational assets for the spring market, with basic chemicals and industrial technology being highlighted as higher elasticity directions. The technology sector is expected to rebound, focusing on innovative pharmaceuticals and national defense industries [9][10] - Specific sectors such as AI computing power, storage, energy storage, and robotics are anticipated to have rebound opportunities in the spring [9][10] - The report includes quantitative sentiment indicators and ETF tracking data, providing insights into market dynamics and investor sentiment [2][17]

Group 1 - The A-share market in 2025 is characterized by a split sentiment, with the index near a ten-year high at around 4000 points, yet many investors feel confused and indifferent despite the apparent bullishness [5][21][22] - The first quarter of 2025 saw a surge in interest in humanoid robots and smart manufacturing, driven by Tesla's advancements, which highlighted China's strong manufacturing capabilities [7][9] - The second quarter shifted focus to innovative drugs in the Hong Kong market, marking a significant re-evaluation of the value of Chinese R&D capabilities, particularly as global pharmaceutical companies faced patent cliffs [10][12] - In the third quarter, the narrative turned to the return of computing power and a shift in investor bias, as the AI hardware sector experienced a significant valuation reassessment due to increased demand from major tech companies [14][18] Group 2 - The market's main themes throughout the year—robots, innovative drugs, and computing power—were initially ignited by overseas demand, with domestic industries amplifying this momentum [20][22] - The current market environment is described as a "not present" bull market, where excitement stems from foreign developments rather than domestic innovations, leading to a sense of detachment among local investors [23][25] - Various investment strategies are being employed to navigate the current chaotic market, with a multi-strategy approach proving effective in maintaining stable returns amidst volatility [26][29]

Core Viewpoint - The article emphasizes the need to shift the focus in innovative drug investment from "people" to "assets," highlighting the importance of molecules, technologies, and pipelines with significant therapeutic potential and commercial value in the biopharmaceutical sector [5][6]. Group 1: Investment Strategy - Vivo Capital has adopted a new approach called the "accelerator" model, which involves selecting high-quality drug assets globally and establishing new companies (NewCo) to introduce them to China, leveraging China's integrated advantages in clinical trials and resource allocation [6][12]. - The firm has raised $740 million for its public market strategy and currently manages over $7.5 billion in assets, indicating a robust investment capacity [6][8]. - The traditional VC model in biopharmaceuticals is deemed ineffective, as it has led to resource misallocation and excessive reliance on capital markets, which can jeopardize drug development when IPO opportunities diminish [8][9]. Group 2: Market Dynamics - In the first half of 2025, China saw a total upfront payment of approximately $2.64 billion for innovative drug license-out transactions, surpassing the primary market financing total of about $1.62 billion [8]. - The article notes a significant gap between the investment in innovative drugs (approximately $200 billion over the past decade) and the projected annual sales of domestic innovative drugs in 2024 (around 60 billion RMB, or less than $10 billion) [9]. - The article highlights that the investment returns in sectors like food, pharmaceuticals, and aviation are often marginally negative due to their substantial social value, advising investors from non-biopharmaceutical sectors to be cautious [9]. Group 3: Asset Development and Evaluation - The asset development process involves a five-tier evaluation system, including assessments from the original technology company, Vivo Capital, the NewCo board, development partners, and potential buyers [13]. - The decision to advance or halt a project is influenced by both scientific data and dynamic market competition, ensuring efficient resource allocation [13]. - Vivo Capital's investment strategy has evolved through three iterations, culminating in the establishment of the "accelerator" model, which focuses on resource allocation around promising assets [13][19]. Group 4: Leadership and Team Dynamics - The selection of leadership for new ventures is critical, with a focus on finding "drivers" who possess international perspectives and resource integration capabilities rather than traditional founders [18]. - The article emphasizes the need for a collaborative approach among various talent types, including those who identify market needs, researchers, and business development professionals [15][16]. - The challenge lies in accurately assessing individuals' capabilities in a complex and high-barrier industry, where misalignment can lead to resource misallocation [16]. Group 5: Market Outlook - The article expresses optimism about the long-term prospects of the Hong Kong stock market for innovative drugs, despite a recent correction, citing improved asset quality compared to three years ago [20][21]. - Factors contributing to the positive outlook include regulatory alignment with international standards, the return of overseas experts, the rise of specialized service platforms, and substantial capital inflows [21][22]. - The article notes that global pharmaceutical companies currently have approximately $1.2 trillion in available funds, creating opportunities for domestic innovative drug companies to engage in business development transactions [23].

Core Viewpoint - The "Xingyao Navigation Plan" aims to create a leading platform for private equity in China's technology innovation sector, focusing on the unique role of state-owned private equity in supporting technological innovation and local economic development [1] Group 1: Investment Strategy - Lianhai Lukuo Fund has prioritized technological innovation since its establishment in 2022, focusing on strategic emerging industries such as biomedicine, artificial intelligence, and high-end manufacturing [1][2] - The fund has maintained a long-term holding of over 50% in innovative drug sectors within its stock strategy products, leveraging its background in the financial industry [1] Group 2: Long-term Growth Assessment - The company emphasizes long-term growth potential by evaluating factors such as R&D investment, patent layout, and policy environment, rather than just current financial performance [2] - Lianhai Lukuo Fund has developed a digital investment research system to enhance its investment strategies and risk assessments [2] Group 3: Social Responsibility - The fund actively promotes social responsibility through initiatives in public welfare, talent development, and investor education [3] - It has established a long-term public welfare mechanism and collaborates with educational institutions to nurture professional talent [3] Group 4: Regional Economic Support - As the only private equity fund manager in Lianyungang, the company plays a crucial role in matching local technology enterprises with long-term funding needs, addressing the gap between short-term funding and long-term projects [3] Group 5: Future Outlook - The company plans to increase investments in the technology sector and enhance its digital research capabilities while continuing to fulfill its social responsibilities [4]